Lifecore Biomedical, Inc. (LFCR)
| Market Cap | 243.36M -16.1% |
| Revenue (ttm) | 106.46M -18.6% |
| Net Income | -74.94M |
| EPS | -1.99 |
| Shares Out | 37.91M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 93,996 |
| Open | 6.40 |
| Previous Close | 6.40 |
| Day's Range | 6.38 - 6.42 |
| 52-Week Range | 3.63 - 8.98 |
| Beta | 0.97 |
| Analysts | Hold |
| Price Target | 6.28 (-2.18%) |
| Earnings Date | Nov 4, 2026 |
About LFCR
Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization that serves customers in the United States, Belgium, the Netherlands, and internationally. It provides services in the development, manufacture, aseptic fill, and finish of formulations and highly viscous sterile injectable pharmaceutical drug or medical device products in syringes, vials, and cartridges in various modalities. The company also manufactures and sells pharmaceutical-grade hyaluronic acid in bulk... [Read more]
Financial Performance
In 2025, Lifecore Biomedical's revenue was $129.46 million, an increase of 0.46% compared to the previous year's $128.87 million. Losses were -$34.50 million, -22.22% less than in 2025.
Financial StatementsAnalyst Summary
According to 5 analysts, the average rating for LFCR stock is "Hold." The 12-month stock price target is $6.28, which is a decrease of -2.18% from the latest price.
News
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: ADT Inc. (NYSE – ADT), RXO Inc. (NYSE – RXO), PTC Inc. (Nasdaq – PTC), Lifecore Biomedical, Inc. (Nasdaq – LFCR)
BALA CYNWYD, Pa., Nov. 11, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (j...
Lifecore Biomedical Proxy statement: Proxy filing
Lifecore Biomedical filed a proxy statement on November 5, 2026, providing details for shareholder voting and corporate governance matters.
Lifecore reports Q3 EPS ($1.08), consensus (30c)
Reports Q3 revenue $25.32M, consensus $25.57M. “During the third quarter, Lifecore (LFCR) secured two new technology transfer projects. One will support process performance qualification batches for a...
Lifecore Biomedical Reports Financial Results for the Third Quarter Ended September 30, 2026, and Provides Corporate Update
-- Multiple New Business Wins Continue to Strengthen Growing Pipeline -- CHASKA, Minn., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated inje...
Lifecore Biomedical Quarterly report: Q1 2027
Lifecore Biomedical has published its Q1 2027 quarterly earnings report on November 4, 2026.
Lifecore Biomedical Earnings release: Q1 2027
Lifecore Biomedical released its Q1 2027 earnings on November 4, 2026, summarizing the period's financial results.
Lifecore Biomedical Proxy statement: Proxy filing
Lifecore Biomedical filed a proxy statement on October 30, 2026, providing details for shareholder voting and corporate governance matters.
Lifecore Biomedical to Participate at Upcoming Industry Conferences
CHASKA, Minn., Oct. 07, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated injectables contract development and manufacturing organization (“CDMO”), tod...
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: RXO Inc. (NYSE – RXO), PTC Inc. (Nasdaq – PTC), Lifecore Biomedical, Inc. (Nasdaq – LFCR), WaFd, Inc. (Nasdaq – WAFD)
BALA CYNWYD, Pa., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (j...
Halper Sadeh LLC is Investigating Whether LFCR and SSTI are Obtaining Fair Deals for their Shareholders
Insiders may stand to receive substantial financial benefits not available to ordinary shareholders.
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Capital Bancorp, Inc. (Nasdaq – CBNK), Lifecore Biomedical, Inc. (Nasdaq – LFCR), MISTRAS Group, Inc. (NYSE – MG), Utz Brands, Inc. (NYSE – UTZ)
BALA CYNWYD, Pa., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (...
SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Lifecore Biomedical, Inc. (LFCR)
Bala Cynwyd, Pennsylvania--(Newsfile Corp. - September 29, 2026) - Law office of Brodsky & Smith announces that it is investigating potential claims against the Board of Directors of Lifecore Biomedic...
Lifecore downgraded to Market Perform from Outperform at Barrington
Barrington downgraded Lifecore (LFCR) to Market Perform from Outperform after the company agreed to be acquired by private equity firm Webster Equity Partners for $6.28 per share in cash at…
Lifecore downgraded to Hold from Buy at Craig-Hallum
Craig-Hallum analyst Matthew Hewitt downgraded Lifecore (LFCR) to Hold from Buy with a $6.28 price target after the company agreed to be acquired by private equity firm Webster Equity Partners…
Lifecore downgraded to Market Perform from Outperform at William Blair
William Blair analyst Jared Haase downgraded Lifecore (LFCR) to Market Perform from Outperform after the company announced that it has entered into a definitive agreement to be acquired by private…
Lifecore Biomedical trading resumes
09:55 EDT Lifecore (LFCR) Biomedical trading resumes
Lifecore to be acquired by Webster Equity Partners for $6.28 per share in cash
Lifecore (LFCR) Biomedical announced that it has entered into a definitive agreement to be acquired by Webster Equity Partners in a transaction valued at up to $663.7M, assuming full achievement…
Lifecore Biomedical to be Acquired by Webster Equity Partners
Lifecore Common Stockholders to Receive $6.28 per Share in Cash at Closing, Representing a 49.5% Premium Lifecore Series A Preferred Stockholders Will Receive Required “Conversion Amount” per Share i...
Lifecore Biomedical trading halted, news pending
08:40 EDT Lifecore (LFCR) Biomedical trading halted, news pending
Lifecore Biomedical Proxy statement: Proxy filing
Lifecore Biomedical filed a proxy statement on September 28, 2026, providing details for shareholder voting and corporate governance matters.
Lifecore Biomedical to Participate at CPHI Global Conference
CHASKA, Minn., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated injectables contract development and manufacturing organization (“CDMO”), to...
Lifecore signs agreement for commercial site transfer for pharmaceutical company
Lifecore (LFCR) announced it has signed a new agreement to transfer a commercially marketed product to the company’s pipeline. Under the terms of the agreement, Lifecore will perform technical transfe...
Lifecore Biomedical Signs Agreement for Commercial Site Transfer Supporting Global Pharmaceutical Company
-- Significant New Program Positioned to Become One of Lifecore's Largest Contracts -- -- Agreement Supports Tech Transfer and Commercial Manufacturing of Currently Marketed Drug Product -- -- Program...
Lifecore price target lowered to $6.25 from $6.50 at Barrington
Barrington analyst Michael Petusky lowered the firm’s price target on Lifecore (LFCR) to $6.25 from $6.50 and keeps an Outperform rating on the shares. The firm views the company’s Q2…
Lifecore Biomedical Earnings Call Transcript: Q2 2026
Q2 revenue and profit declined year-over-year, but cost reductions and new business wins support reaffirmed 2026 guidance. Strong HA manufacturing and CDMO momentum, combined with industry tailwinds and operational improvements, position the company for mid- and long-term growth.